LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solutions, with manufacturing capacities located in the United States at LTS' Lakewood, New Jersey facility.

The new offering focuses initially on product development through clinical manufacturing of sterile ophthalmic products, filled in preservative–free multidose devices. Leveraging its established commercial aseptic manufacturing capabilities in nasal sprays and vials, LTS is well positioned to meet the high quality and regulatory demands of ophthalmic treatments, including products for chronic and acute eye conditions.

Building on decades of experience in drug delivery technologies, LTS ultimately plans to offer end–to–end CDMO services for ophthalmic drug products, ranging from formulation development through commercial manufacturing. All activities will be conducted in compliance with global regulatory standards, supporting both U.S. and international market requirements.

"Ophthalmic drug delivery presents unique challenges in terms of sterility, efficacy, and patient safety," said Bas van Buijtenen, CEO at LTS. "Our aseptic manufacturing capabilities in Lakewood, are the perfect foundation to build industry-leading CDMO capabilities and capacity for ophthalmics, powering the future of drug delivery in this field in North America. We look forward to extending our purpose - We CARE. We CREATE. We DELIVER -towards an even wider group of customers, therapies and patients."

The expanded CDMO services are intended to support pharmaceutical and biotech companies seeking a reliable U.S.-based manufacturing partner for ophthalmic drug delivery solutions. By combining development expertise, sterile manufacturing infrastructure, and a strong quality culture, LTS aims to act as a long–term partner across the entire product lifecycle.

This portfolio expansion reflects LTS's strategic commitment to continuously broaden its technology and service offerings and to address growing demand for specialized drug delivery solutions in sensitive therapeutic areas.